Good Doctor·Hyperthermic Intraperitoneal Chemotherapy | Literature Review | Clinical Advances and Future Explorations of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastases from Colorectal Cancer

Colorectal cancer is one of the most common malignancies worldwide, posing a serious threat to human health. Each year, approximately 1.926 million new cases of colorectal cancer are diagnosed globally, and about 904,000 deaths are attributed to this disease.


2026-08-21

Colorectal cancer is one of the most common malignancies worldwide and poses a serious threat to human health. Worldwide, approximately 1.926 million new cases of colorectal cancer are diagnosed each year, and about 904,000 people die from the disease [1]. According to estimates from GLOBOCAN 2022, China reported 577,100 new cases of colorectal cancer, making it the second most common malignancy, with an incidence rate of 20.1 per 100,000. There were 240,000 deaths, corresponding to a mortality rate of 8.56 per 100,000, ranking fourth among cancers [2]. Metastasis and recurrence are the leading causes of death in patients with colorectal cancer; peritoneal metastasis is a frequent site of spread, second only to liver and lung metastases, yet its prognosis is significantly poorer than that of hepatic or pulmonary metastases. Approximately 7% to 15% of colorectal cancers are already accompanied by peritoneal metastases at initial diagnosis [3], and 4% to 19% of patients develop peritoneal metastases after curative surgery [4]. Colorectal peritoneal metastases (CRCPM) have a very poor prognosis; without aggressive treatment after diagnosis, The median overall survival (mOS) is only 6 to 9 months [5, 6, 7]. The more severe the peritoneal metastasis, the poorer the prognosis and the shorter the survival time [7].

Comparative schematic diagram of colorectal cancer metastasis and progression

Prior to the 1990s, peritoneal metastases were regarded as an end-stage condition unresponsive to treatment, typically managed only with palliative symptomatic care. Due to the influence of the blood–peritoneum barrier, systemic chemotherapy has shown limited efficacy against peritoneal metastatic lesions [5, 6, 7]. With advances in research, the development of novel agents, and innovations in therapeutic techniques, patients with colorectal cancer presenting with peritoneal metastases can now receive more aggressive treatment strategies, leading to significant improvements in prognosis for those with a lower tumor burden. Since the 1990s, Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS), leveraging the synergistic effects of “hyperthermia, localized high‑concentration chemotherapy, mechanical irrigation, and immune modulation,” has emerged as an important local treatment option for patients with peritoneal carcinomatosis from colorectal cancer. Based on the findings of numerous randomized controlled clinical trials from both Eastern and Western settings, we offer a brief review of the current status and future prospects of CRS combined with HIPEC for the treatment of peritoneal metastases from colorectal cancer, as follows:

 

Past: Establishment of the Theoretical Foundation and Early Exploration (1980s–2010)

Establishment of the Theoretical Foundation

The theoretical foundation of HIPEC stems from an extension of the concept of peritoneal dialysis. Due to the presence of the blood–peritoneum barrier, intraperitoneal drug concentrations after systemic intravenous chemotherapy fall far short of the effective therapeutic levels, whereas intraperitoneal administration can achieve drug concentrations that are several to hundreds of times higher than those achieved with systemic intravenous delivery, while limiting systemic toxicity. Meanwhile, hyperthermia itself exerts direct cytotoxic effects: normal peritoneal organ‑derived cells can tolerate 45°C for one hour, whereas tumor cells suffer irreversible damage at 43°C for one hour. Hyperthermia at 42–43°C also sensitizes cancer cells to chemotherapeutic agents, increases tumor vascular permeability, and enhances the depth of chemotherapeutic drug penetration. Furthermore, the combined action of hyperthermia and chemotherapy can induce immunogenic cell death (ICD), thereby triggering an antitumor immune response [8]. These theoretical underpinnings have established the clinical basis for the use of HIPEC in the treatment of malignant peritoneal tumors.

 

Early-stage clinical preliminary exploration

In 1980, Spratt et al. first applied HIPEC to patients with peritoneal pseudomyxoma, providing preliminary evidence of its safety and feasibility [9].

In 1996, Schneebaum et al. performed CRS followed by one-hour mitomycin‑C HIPEC in 15 patients with peritoneal metastases from colorectal cancer, achieving a median survival of more than six months [10].

In 2000, Witkamp et al. enrolled 29 patients with CRCPM; the 2-year and 3-year survival rates after CRS plus HIPEC were 45% and 23%, respectively [11].

In 2003, Verwaal et al. from the Netherlands published a landmark randomized controlled trial that randomly assigned 105 patients with colorectal cancer peritoneal metastases (crcPM) to either a standard group (palliative surgery plus systemic chemotherapy) or an experimental group (CRS plus HIPEC plus systemic chemotherapy). The results showed a median survival of 12.6 months in the control group versus 22.3 months in the experimental group (P=0.032) [12]. Eight-year follow-up data further demonstrated that patients achieving R0/R1 resection had a 5-year survival rate of 45% [13]. This study provided the first high-level evidence demonstrating that CRS plus HIPEC can significantly improve survival in patients with crcPM, marking a shift in the management of this condition from “incurable” to “actively treatable.” A subsequent multicenter French study involving 523 patients confirmed that the median survival for those undergoing CRS plus HIPEC was 30 months, with complete cytoreduction (CC-0) identified as an independent prognostic factor [14].

 

Early Controversies and Limitations

However, early clinical studies of HIPEC for CRC‑PM have several limitations: small sample sizes, predominantly single‑center retrospective designs, and a lack of standardized perfusion protocols—regarding drug selection, duration, and temperature. Western guidelines (ESMO, NCCN) adopt a more conservative stance on CRS plus HIPEC, largely due to the absence of large, randomized controlled trial data, the substantial surgical trauma involved, and the high risk of complications. In the early years, mitomycin C and platinum agents were the main perfusion drugs, but dosing regimens and treatment durations varied considerably. Patient selection criteria also lacked uniformity, and a standardized PCI (Peritoneal Cancer Index) stratification system had yet to be established; consequently, patients with high tumor burden derived only limited postoperative benefit.

 

Current Situation: Evidence Differentiation and Precision Stratification (2011–2026)

Patient stratification criteria have been established, with the Peritoneal Cancer Index (PCI) and the Complete Cytoreductive Surgery (CC) score serving as the core screening metrics.

As research has advanced, the PCI score and the CC (cytoreductive completeness) score have become key criteria for screening patients with CRC‑PM. The PCI divides the abdomen into 13 regions and assigns scores based on lesion size (LS0: no tumor; LS1: ≤0.5 cm; LS2: 0.5–5 cm; LS3: >5 cm or coalescing into a mass), with the total score reflecting peritoneal tumor burden [15]. The CC score assesses the extent of cytoreduction: CC‑0 (no residual disease), CC‑1 (residual disease ≤2.5 mm), CC‑2 (residual disease 2.5 mm–2.5 cm), and CC‑3 (residual disease >2.5 cm) [16].

Multicenter studies have consistently demonstrated that a PCI score of less than 20, combined with the ability to achieve complete cytoreduction—CC‑0 or CC‑1—is the critical threshold for CRCPM patients to derive clinical benefit from CRS plus HIPEC. It should be noted that the PCI threshold is not an absolute value; it must be assessed in conjunction with the feasibility of CC resection and the patient’s performance status. A French multicenter study involving 523 cases reported a median survival of 30 months among CRCPM patients who underwent CRS plus HIPEC, with complete CRS emerging as an independent prognostic factor [14]. Domestic research has likewise confirmed that CRS combined with HIPEC can prolong survival in selected patients with metachronous peritoneal metastases from colorectal cancer—i.e., recurrences following curative surgery—with a median survival of 22.1 months and a 12‑month survival rate of 78.1%. The PSDSS (Peritoneal Surface Disease Severity Score), which integrates clinical symptoms, PCI findings, and pathological characteristics, serves as an independent prognostic factor for CRCPM patients [17, 18]. Currently, a standardized preoperative imaging evaluation–diagnostic laparoscopy protocol has been established in clinical practice.

Schematic diagram of Peritoneal Cancer Index (PCI) staging

Optimization of Infusion Protocols and Drug Selection

For HIPEC perfusion agents used in peritoneal metastases from colorectal cancer, no unified standard has yet been established across centers. Commonly employed drugs include mitomycin C, oxaliplatin, cisplatin, lobaplatin, raltitrexed, and 5-fluorouracil. Mitomycin C, with favorable pharmacokinetic properties and low peritoneal toxicity, is one of the most widely used agents in HIPEC for treating CRC‑PM; the typical dose is 35 mg/m² [19]. A landmark RCT by Verwaal et al., which utilized mitomycin C (35 mg/m² administered over 90 minutes), demonstrated survival benefits with this regimen. Caution is advised regarding the potential for bone marrow suppression as an adverse effect of mitomycin C.

In recent years, oxaliplatin, a first-line chemotherapeutic agent for metastatic colorectal cancer, has also been employed in HIPEC; the most common regimens involve either 460 mg/m² infused over 30 minutes or 200 mg/m² infused over 2 hours [20]. Preclinical studies have demonstrated that prolonging the infusion duration (to 90–120 minutes) is more effective than simply increasing the drug dose while maintaining a short infusion time (e.g., a high dose administered over 30 minutes). A multi-institutional retrospective study indicated that mitomycin C yielded significantly superior disease-free survival and peritoneal disease-free survival compared with oxaliplatin. Furthermore, both animal experiments and organoid models have confirmed that an oxaliplatin regimen of 200 mg/m² infused over 2 hours is more efficacious than a 460 mg/m² infusion over 30 minutes in inducing tumor cell apoptosis [20, 21]. Clinical use of oxaliplatin requires careful monitoring for associated intra-abdominal toxicities. Lobaplatin, a third-generation platinum agent, possesses a larger molecular weight and poor permeability across the peritoneal barrier, enabling sustained high intraperitoneal drug concentrations with minimal adverse effects. It has already been widely adopted in domestic hyperthermic intraperitoneal chemotherapy protocols; however, most available evidence derives from single-center retrospective studies, and robust large-scale randomized controlled trials remain lacking [22].

 

Prophylactic HIPEC: From Controversy to Positive Evidence

For patients at high risk of peritoneal metastasis, such as those with T4 disease or tumor perforation, prophylactic HIPEC has become a research focus; however, current national and international guidelines do not yet endorse it as a standard clinical practice, and its use is generally restricted to settings involving rigorous multidisciplinary team (MDT) assessment or clinical trials.

The COLOPEC trial (Netherlands, 204 patients with T4 or perforated colorectal cancer) compared the efficacy of oxaliplatin-based HIPEC (460 mg/m², 30 minutes) administered 5–8 weeks after surgery with that of surgery alone. The results showed no significant difference in peritoneal metastasis-free survival at 18 months (76.2% vs. 80.9%, P=0.28); 5-year follow-up data likewise failed to demonstrate any survival benefit [23, 24]. However, when patients with crcPM who had already been found to have peritoneal metastases prior to prophylactic HIPEC were excluded, the HIPEC group exhibited a markedly lower rate of peritoneal recurrence (10%) compared with the control group (23%).

The PROPHYLOCHIP‑PRODIGE 15 trial (France, 150 high-risk patients) compared second-look surgery plus HIPEC with conventional surveillance; the results showed no significant difference in 3-year disease-free survival (44% vs. 53%, HR = 0.97), and the second-look group had a higher rate of complications [25].

In stark contrast, the HIPECT4 trial (Spain), which employed intraoperative mitomycin C–based HIPEC, demonstrated that the HIPEC group achieved a significantly higher 3-year local control rate than the control group (97.6% vs. 87.6%; HR = 0.19; P = 0.031). This approach markedly reduced the rate of peritoneal recurrence in patients with locally advanced colon cancer without increasing toxicity [26, 27]. The HIPECT4 trial was the first randomized controlled study to show that prophylactic intraoperative HIPEC can improve local peritoneal control; however, its overall survival benefit remains to be further confirmed. Differences in the timing of perfusion (intraoperative vs. postoperative) and in the perfusate agent (mitomycin C vs. oxaliplatin) may be key factors accounting for the inconsistent results across various trials.

 

CRS is critical: complete tumor debulking determines patient prognosis.

Multiple studies have consistently demonstrated that the completeness of cytoreductive surgery (CRS) is a key determinant of patient prognosis. Research by Verwaal et al. indicates that patients with minimal residual disease (tumor remnants <2.5 mm) or no residual disease experience a significantly improved median survival, whereas HIPEC does not confer a clear survival benefit in patients with substantial tumor residuals. Therefore, to maximize clinical benefit for patients with colorectal cancer peritoneal metastases (crcPM), adjuvant HIPEC should be administered only when CRS has achieved thorough removal of tumor tissue. Current consensus holds that, for patients who attain CC‑0 or CC‑1 complete cytoreduction, HIPEC may offer additional local control benefits [28]. At the same time, attention must be paid to the perioperative complication risks associated with CRS plus HIPEC; this approach carries potential complications such as acute kidney injury, bone marrow suppression, hepatic dysfunction, nausea, vomiting, and fever, and should be performed at appropriately equipped medical centers.

 

Minimally Invasive HIPEC and Comprehensive Treatment Paradigm

Laparoscopic CRS combined with HIPEC is being increasingly adopted, reducing the invasiveness of traditional open surgery. Meanwhile, a multimodal, comprehensive treatment approach has been established: for patients with high tumor burden at initial diagnosis—specifically those with peritoneal carcinomatosis (crcPM)—systemic neoadjuvant therapy may be administered first to shrink the tumor and downstage the disease, followed by reassessment of whether CRS combined with HIPEC is feasible, thereby maximizing the chance of curative intent. Sammartino et al. [29], in a retrospective study, reported that among patients who received prophylactic HIPEC postoperatively, the rate of peritoneal metastases decreased from 22.0% to 4.0%, and progression-free survival was significantly prolonged (36.8 months vs. 21.9 months; P < 0.01).

 

Differences in Evidence Between East and West and Guideline Positioning

A multicenter, prospective study from Asia overall supports the survival benefits of CRS plus HIPEC. The current Chinese expert consensus (2022 edition) recommends that, following a thorough assessment of tumor burden, CRS combined with HIPEC may be selectively employed at experienced centers for resectable CRC‑PM patients [28]. The Chicago Consensus (2020) designates CRS plus HIPEC as one of the standard treatment options for CRC‑PM [30].

 

The Future: Precision, Personalization, and the Integration of New Technologies

□ Precision Screening and Molecular Stratification

Liquid biopsies—assessing peritoneal free tumor cells and circulating tumor DNA (ctDNA)—hold promise for predicting peritoneal micrometastases and identifying high-risk patients who would benefit from prophylactic HIPEC. However, this technology remains in the clinical research phase and has not yet been routinely adopted for clinical screening. Molecular subtyping is emerging as a guiding principle for personalized therapy: biomarkers such as the CMS4 subtype, RAS/RAF mutations, and microsatellite instability status can help select patients most likely to derive optimal benefit from CRS plus HIPEC. Risk factors for peritoneal metastasis in colorectal cancer include primary tumor perforation, synchronous ovarian metastases, non‑R0 resection of the primary lesion, T4 disease and/or N+ staging, and inadequate intraoperative lymph node sampling of fewer than 12 nodes [31, 32]. Artificial intelligence–based prognostic models incorporating peritoneal chemotherapy index scores and tumor markers may enable precise prediction of whether patients with colorectal cancer–related peritoneal metastases will benefit from HIPEC.

 

□ The HIPEC protocol continues to evolve.

Schemes to prolong perfusion duration are currently undergoing multicenter, randomized validation. Combining intraperitoneal targeted therapy with immunotherapy and hyperthermic perfusion represents a new frontier: intraperitoneal PD‑1 inhibitors combined with hyperthermia synergistically eradicate peritoneal micrometastases. Tumor organoid models can assess a patient’s sensitivity to perfusion agents within the clinical therapeutic window, thereby enabling the personalized selection of the most effective perfusion regimen [21].

 

□ Novel Intraperitoneal Drug Delivery Technology

Pressurized intraperitoneal aerosol chemotherapy (PIPAC), as a palliative treatment for patients who are not candidates for CRS, is currently being investigated in clinical trials [33]. Robotic CRS combined with real-time temperature monitoring and uniform perfusion systems holds promise for enhancing surgical precision and achieving more uniform perfusion.

 

□ Further validation of prophylactic HIPEC

Existing clinical trials suggest that intraoperative prophylactic HIPEC with mitomycin C may confer benefits in local disease control, though the evidence remains limited. Ongoing multicenter randomized trials will further delineate the optimal indications, timing of perfusion, and choice of agents for prophylactic HIPEC. For patients at high risk of peritoneal metastases, selective implementation of preoperative prophylactic HIPEC—following thorough multidisciplinary team discussion—represents a promising avenue worthy of exploration [28].

In the past, peritoneal metastases from colorectal cancer were considered a terminal condition with extremely limited treatment options. Today, CRS plus HIPEC has emerged as an important therapeutic option for certain patients with CRC‑PM, and those with low PCI scores who can achieve complete cytoreduction (CC‑0/CC‑1) may experience substantial survival benefits. [13, 14] Looking ahead, the field is moving toward molecularly guided risk stratification, individualized perfusion regimens, prophylactic application, and minimally invasive, intelligent approaches. Large randomized trials will help standardize global treatment protocols, fundamentally challenging the longstanding notion that peritoneal metastases from colorectal cancer are incurable. Nevertheless, this therapy still requires multidisciplinary team (MDT) collaboration, should be performed at centers with specialized expertise in peritoneal malignancies, and demands rigorous adherence to surgical cytoreduction criteria and patient selection guidelines.

 

References

【1】Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74(3): 229‑263.

[2] Chinese Anti-Cancer Association. Chinese Guidelines for Integrated Cancer Diagnosis and Treatment (Second Edition). 2024:1527.

【3】Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg, 2006, 243(2):212‑222.

【4】Klaver YL, Lemmens VE, Nienhuijs SW, Luyer MD, de Hingh IH. Peritoneal carcinomatosis of colorectal origin: Incidence, prognosis and treatment options. World J Gastroenterol, 2012, 18(39):5489‑5494.

【5】Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of North Central Cancer Treatment Group phase III trials N9741 and N9841. J Clin Oncol, 2012, 30(3):263‑267.

【6】Foster JM, Zhang C, Rehman S, Sharma P, Alexander HR. The contemporary management of peritoneal metastasis: a journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin, 2023, 73(1):49‑71.

【7】Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer, 2011, 128(11):2717‑2725.

【8】Al‑Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol, 2008, 14(8):1159‑1166.

【9】Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res, 1980, 40(2):256‑260.

[10] Schneebaum S, Arnold MW, Staubus A, Young DC, Dumond D, Martin EW Jr. Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol, 1996, 3(6):453‑460.

【11】Witkamp AJ, de Bree E, Kaag MM, Boot H, Beijnen JH, van Slooten GW, van Coevorden F, Zoetmulder FA. Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol, 2000, 26(7):670‑675.

[12] Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol, 2003, 21(20):3737‑3743.

[13] Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol, 2008, 15(9): 2426–2432.

【14】Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, DubèP, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol, 2010, 28(1):63‑68.

【15】Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol, 2009, 16(2):327‑333.

【16】Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol, 1999, 43(Suppl): S15‑S25.

【17】Esquivel J, Lowy AM, Markman M, Chua T, Glenn D, Morris DL. The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis. Ann Surg Oncol, 2014, 21(13):4195‑4201.

【18】Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M. Colorectal peritoneal metastases treated by perioperative systemic chemotherapy and cytoreductive surgery with or without mitomycin C‑based HIPEC: a comparative study using the peritoneal surface disease severity score (PSDSS). Ann Surg Oncol, 2020, 27(1):98‑106.

【19】Yurttas C, Hoffmann G, Tolios A, Haen SP, Schwab M, Königsrainer I, Königsrainer A, Beckert S, Löffler MW. Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal cancer. J Clin Med, 2018, 7(12):567.

【20】Bhatt A, de Hingh I, Van Der Speeten K, Hubner M, Deraco M, Bakrin N, Villeneuve L, Kusamura S, Glehen O. HIPEC Methodology and Regimens: The Need for an Expert Consensus. Ann Surg Oncol, 2021, 28(13):9098‑9113.

【21】Forsythe SD, Sasikumar S, Moaven O, Sivakumar H, Shen P, Levine EA, Soker S, Skardal A, Votanopoulos KI. Personalized identification of optimal HIPEC perfusion protocol in patient‑derived tumor organoid platform. Ann Surg Oncol, 2020, 27(13):4950‑4960.

[22] Wang Lei, Zhang Tao, Li Gang, et al. Clinical observation of intraperitoneal hyperthermic perfusion chemotherapy with lobaplatin for peritoneal metastases from colorectal cancer. Chinese Journal of General Surgery, 2021, 36(8):589‑593.

[23] Klaver CEL, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, Brandt A, Bremers AJA, Burger JWA, Fabry HFJ, Ferenschild F, Festen S, van Grevenstein WMU, Hemmer PHJ, de Hingh IHJT, Lammers LA, van Lijnschoten I, Meijerink MR, Nienhuijs SW, Rietjens SJ, Rutten HJT, Schouten SB, van der Speet K, van der Stok EP, van der Velden AWG, Verheul HMW, Wasowicz DK, Zimmerman DDE, van Tinteren H, Verwaal VJ, van de Vijver MJ, van der Vliet HJ, Wiezer MJ, de Wilt JHW, Tuynman JB. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Lancet Gastroenterol Hepatol, 2019, 4(10):761‑770.

[24] Zwanenburg ES, El Klaver C, Wisselink DD, Punt CJA, Snaebjornsson P, Crezee J, Aalbers AGJ, Brandt A, Bremers AJA, Burger JWA, Fabry HFJ, Ferenschild F, Festen S, van Grevenstein WMU, Hemmer PHJ, de Hingh IHJT, Lammers LA, van Lijnschoten I, Meijerink MR, Nienhuijs SW, Rietjens SJ, Rutten HJT, Schouten SB, van der Speet K, van der Stok EP, van der Velden AWG, Verheul HMW, Wasowicz DK, Zimmerman DDE, van Tinteren H, Verwaal VJ, van de Vijver MJ, van der Vliet HJ, Wiezer MJ, de Wilt JHW, Tuynman JB. Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Colon Cancer (COLOPEC): 5-Year Results of a Randomized Multicenter Trial. J Clin Oncol, 2024.

[25] Goéré D, Glehen O, Quenet F, Guilloit JM, Bereder JM, Lorimier G, Thibaudeau E, Ghouti L, Pinto A, Tuech JJ, Kianmanesh R, Carretier M, Marchal F, Arvieux C, Brigand C, Meeus P, Roca L, Pocard M. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP‑PRODIGE 15): a randomised, phase 3 study. Lancet Oncol, 2020, 21(9):1147‑1154.

【26】Arjona‑Sánchez A, Barrios P, Boldo‑Roda E, Camps B, Carrasco‑Campos J, Concepción Martin V, García‑Fadrique A, Gutiérrez‑Calvo A, Morales R, Ortega‑Pérez G, Pérez‑Viejo E, Prada‑Villaverde A, Torres‑Melero J, Tur‑Martínez J. HIPECT4: multicentre, randomized clinical trial to evaluate safety and efficacy of Hyperthermic intra‑peritoneal chemotherapy (HIPEC) with Mitomycin C used during surgery for treatment of locally advanced colorectal carcinoma. BMC Cancer, 2018, 18(1):183.

【27】Arjona‑Sánchez A, Gutiérrez‑Calvo A, Segura‑Sampedro JJ, Morales R, et al. Efficacy and safety of intraoperative hyperthermic intraperitoneal chemotherapy for locally advanced colorectal cancer (HIPECT4): final analysis of randomized clinical trial. BJS Open, 2022.

[28] Committee of Peritoneal Tumors, Colorectal Oncology Professional Committee, Chinese Medical Association. Chinese Expert Consensus on the Diagnosis and Treatment of Peritoneal Metastasis from Colorectal Cancer (2022 Edition). Chinese Journal of Digital Medicine in Colorectal Diseases, 2022, 11(4): 265–271.

【29】Sammartino P, Sibio S, Biacchi D, Cardelli R, Accarpio F, Impagnatiello A, Di Giorgio A. Prevention of peritoneal metastases from colon cancer in high‑risk patients: Preliminary results of surgery plus prophylactic HIPEC. Gastroenterol Res Pract, 2012, 2012:141585.

【30】Chicago Consensus Working Group. The Chicago Consensus on peritoneal surface malignancies: Management of colorectal metastases. Ann Surg Oncol, 2020, 27(6):1761‑1767.

【31】Sadahiro S, Suzuki T, Maeda Y, Tanaka A, Makuuchi H, Kamijo A, Haruki Y, Murayama C. Prognostic factors in patients with synchronous peritoneal carcinomatosis (PC) caused by a primary cancer of the colon. J Gastrointest Surg, 2009, 13(9):1593‑1598.

[32] Li Yan, Zhou Yunfeng, Liang Han, Wang Huaqing, Hao Jihui, Zhu Zhenggang, Wan Desen, Qin Lunxiu, Cui Shuzhong, Ji Jiafu, Xu Huimian, Wei Shaozhong, Xu Hongbin, Suo Tao, Yang Shujun, Xie Conghua, Yang Xiaojun, Yang Guoliang. Expert consensus on cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancies. Chinese Journal of Clinical Oncology, 2015, 42(4):198–206.

【33】Turaga K,Levine E,Barone R,Sticca R,Petrelli N,Lambert L,Nash G,Moore M,Strong V,Uriel S,Esquivel J.Consensus guidelines from the American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy(HIPEC)in colorectal cancer patients in the United States.Ann Surg Oncol,2014,21(5):1501‑1505.

Key words:

Related News